Abstract-␤-Amyloid (A␤), a vasoactive protein, and elevated blood pressure (BP) levels are associated with Alzheimer disease (AD) and possibly vascular dementia. We investigated the joint association of midlife BP and A␤ peptide levels with the risk for late-life AD and vascular dementia. Subjects were 667 Japanese-American men (including 73 with a brain autopsy), from the prospective Honolulu Heart Program/Honolulu Asia Aging Study . Midlife BP was measured starting in 1971 in participants with a mean age of 58 years; A␤ was measured in specimens collected in 1980 -1982, and assessment of dementia and autopsy collection started in 1991-1993. The outcome measures were prevalent (present in 1991-1993) and incident AD (nϭ53, including 38 with no contributing cardiovascular disease) and vascular dementia (nϭ24). Cerebral amyloid angiopathy, ␤-amyloid neuritic plaques, and neurofibrillary tangles were evaluated in postmortem tissue. The risk for AD significantly increased with lower levels of plasma A␤ (A␤1-40 hazard ratio: 2.1 [95% CI: 1.4 to 3.1]; A␤1-42 hazard ratio: 1.6 [95% CI: 1.1 to 2.3]). Evidence of interaction between diastolic BP and plasma A␤ (1-40 P interaction Ͻ0.05; 1-42 P interaction Ͻ0.07) levels indicated that the A␤-related risk for AD was higher when BP was higher. Low plasma A␤ was associated with the presence of cerebral amyloid angiopathy (P trend Ͻ0.05) but not the other neuropathologies. A␤ plasma levels start decreasing Ն15 years before AD is diagnosed, and the association of A␤ to AD is modulated by midlife diastolic BP. Elevated BP may compromise vascular integrity leading to cerebral amyloid angiopathy and impaired A␤ clearance from the brain. A lzheimer disease (AD) has been linked to cardiovascular risk factors, such as diabetes mellitus, hyperlipidemia, and, in particular, elevated blood pressure (BP).
A lzheimer disease (AD) has been linked to cardiovascular risk factors, such as diabetes mellitus, hyperlipidemia, and, in particular, elevated blood pressure (BP).
1,2 Several reports, including one from the Honolulu Asia Aging Study (HAAS), 3, 4 have shown that the risk for late-life AD and cognitive impairment 5 is more closely associated with elevated BP in midlife compared with late life, when BP levels tend to decline, possibly as a consequence of the dementing process. 4, 6 These findings have importantly contributed to our understanding that dementia processes begin early and may involve vascular changes. ␤-Amyloid (A␤) 1-40 and A␤1-42 peptides are present in AD neuropathologic lesions, [7] [8] [9] and it is hypothesized that A␤ peptide abnormalities begin early in the neurodegenerative pathological cascade. 10, 11 However, in addition to neurotoxicity, A␤ peptides also enhance vasoconstriction 12 and contribute to cerebral vascular pathology and dysfunction when deposited in microvessels. 13 Either from increased production or decreased clearance of A␤, 14 abnormal processing of amyloid precursor protein leads to higher levels of A␤ in cortical tissue and vessels and lower levels in the plasma.
A␤1-40 and A␤1-42 levels are the 2 AD biomarkers that can be measured in the plasma and are, thus, feasible to determine in large samples. Several large, community-based studies [15] [16] [17] [18] [19] have reported on the association of plasma A␤ levels to AD. Study results are mixed but do suggest that plasma levels may be differentially associated with the risk for AD and reflect the stage of the disease and patterns of production in and clearance from the brain.
Given the effect of A␤ on the vasculature and the separate associations of A␤ and BP to dementia, the interaction of the 2 factors is of interest in the study of the pathophysiology and prevention of AD. Because the associations of both A␤ and BP may differ depending on the stage of disease in which they are measured, having measures of these exposures years before the clinical onset of disease can contribute to our understanding of the trajectory to AD. Here, we examined the risk for late-life dementia to midlife BP and A␤ measured, on average, 8 years after BP was measured. We hypothesized that high BP would alter the cerebral vasculature, levels of A␤ in the brain, and their association with the risk for dementia. Subjects are Japanese-American men who participated over 30 years in the population-based Honolulu Heart Program (HHP)/HAAS.
Methods

Study Population
The HAAS is an extension of the Honolulu Heart Program (HHP), a longitudinal, population-based study of heart disease and stroke. The HHP cohort consisted of Japanese-American men born from 1900 to 1919 and living on Oahu at the time of the enrollment examination in 1965-1968 (examination 1, nϭ8006). Follow-up HHP exams occurred from 1967-1970 (examination 2, nϭ7498) and from 1971-1974 (examination 3, nϭ6860), with participation rates among survivors of 85.2% and 83.8%, 20 respectively. A lipoprotein substudy (L) was also implemented with exams in 1970 -1972 (L1, nϭ2780), 1975-1978 (L2, nϭ2386) , and 1980 -1982 (L3, nϭ1965). The lipoprotein subsample included a 30% random sample, with the remainder of the sample chosen on the basis of the presence of hyperlipidemia and coronary heart disease. 21 From 1991 to 1993, surviving HHP participants were invited to join the HAAS, 22 and 80% agreed to participate and had a successfully administered test of global cognitive function (examination 4, nϭ3734). Three subsequent follow-up visits (exams 5-7) were conducted through to 2000, the end date of data collected for this analysis. Through the duration of HAAS, the brain of consenting participants was autopsied to evaluate neuropathology. All of the subjects were invited for inclusion in the autopsy substudy, with an emphasis on recruiting cases of dementia. Overall, 23% consented to autopsy, including, as planned a priori, 35% for those with a dementia diagnosis and 17% in the nondemented group. The autopsied cases were not different from nonautopsied decedent cases; similarly, nondemented autopsied cases were similar to nondemented decedents. 23 The study was approved by the institutional review boards of the Kuakini Medical Center, the Honolulu Department of Veterans Affairs, and the National Institute on Aging. All of the participants gave written, informed consent. Consents for autopsy were provided by a next-of-kin family member or a legally authorized alternative.
BP Measurement
At each examination, BP was measured 3 times, 5 minutes apart, on the left arm of a seated subject with a standard sphygmomanometer.
Measures were averaged to provide a mean examination value. For this study, midlife systolic and diastolic BPs were calculated by averaging BP measures from HHP exams 1 and 3. We also calculated pulse pressure from the BP variables.
Plasma A␤ Determinations
Plasma A␤ was measured with a sandwich ELISA developed by Eli Lilly and optimized by the Laboratory for Clinical Biochemistry Research at the University of Vermont College of Medicine. The antibodies, stock standard proteins, and heat-inactivated rat plasma were provided by Eli Lilly. The capture antibody for the A␤1-40 assay was 2G3 and for the A␤1-42 assay was 21F12. Plasma samples were denatured using guanidine hydrochloride. Standard stock RS0546 was diluted to range from 250.0 to 3.9 pg/mL for the A␤1-40 assay. Standard stock RS0548 was diluted to range from 125.00 to 0.49 pg/mL for the A␤1-42 assay. Biotinylated 3D6 was the detection antibody for both assays. Streptavidin-conjugated horseradish peroxidase provided enzyme activity for detection using 3,3=,5,5=-tetramethylbenzidine as a substrate. Interassay coefficients of variation ranged from 3.1% to 7.9% for the A␤1-40 and 12% to 20% for the A␤1-42 assay.
Diagnosis of Dementia
Diagnosis of prevalent dementia at the first late-life visit (examination 4) or incident dementia at subsequent follow-up visits (exams 5-7) has been detailed previously. 22 Briefly, all of the participants were administered the Cognitive Abilities Screening Instrument 24 ; screen-positive subjects underwent further neuropsychological 25 and neurological evaluation, and a proxy was interviewed. Those with a provisional diagnosis of dementia were further evaluated with blood tests and neuroimaging. A neurologist and Ն2 additional physicians with geriatrics and dementia expertise evaluated participant data and came to a consensus diagnosis of dementia based on criteria from the Diagnostic and Statistical Manual of Mental Disorders (3rd edition, revised). 26 AD was diagnosed using the National Institute of Neurological and Communicative Diseases and Stroke/Alzheimer's Disease and Related Disorders Association criteria, 27 and vascular dementia (VaD) was diagnosed using Alzheimer's Disease Diagnostic and Treatment Centers criteria. 28 Dementia of other subtypes included that attributed to Parkinson disease, vitamin B 12 deficiency, head trauma, progressive supranuclear palsy, or subdural hematoma. Subjects could be diagnosed with a primary and contributing subtype of dementia. The most common form of mixed subtypes was AD with cardiovascular disease, which includes subjects with signs and symptoms consistent with diagnostic criteria for AD and VaD.
Neuropathology Assessment
Methods for the HAAS autopsy study have been described previously. 23 Briefly, initial microscopic examinations were done on paraffin-embedded hematoxylin and eosin-stained sections from 32 brain regions. Selected regions were also immunostained for ubiquitin and the 10-D-5 antibody for A␤. Eight micrometer sections of the middle frontal gyrus, superior middle temporal gyri, inferior parietal lobule, and occipital association cortex along the calcarine sulcus were stained by a modified Bielschowsky method. Presence or absence of cerebral amyloid angiopathy (CAA) was assessed in a microscopic examination of parenchymal vessels in 4 neocortical areas, the middle frontal gyrus, superior-middle temporal gyrus, inferior parietal lobule, and occipital association cortex along the calcarine sulcus. Measures were standardized among 3 raters according to published guidelines. 29 Measures of neuritic plaques and neurofibrillary tangles were recorded as the average number of each across 20 neocortical fields.
Putative Confounding Factors
Based on previous studies, the following putative confounders were considered: age, education, apolipoprotein E genotype, 30 and cardiovascular risk factors and disease. The cardiovascular variables included total cholesterol, triglycerides, insulin, and a history of antihypertensive treatment (self-reported from exams 1-3 and ob-tained from the drug vials presented at examination 4); diabetes mellitus (defined as a self-reported doctor's diagnosis of type 2 diabetes mellitus), taking oral hypoglycemic medications or insulin, or fasting and 2-hour glucose levels according to published guidelines 31 ; and coronary and cerebrovascular disease (obtained from the continuous surveillance of hospital discharge and death records on Oahu).
Substudy Sample
To reduce the variability in storage time and based on the availability of stored plasma samples in the largest number of subjects at the same examination cycle, we selected subjects from the third HHP examination (nϭ261) and the third lipoprotein examination (nϭ771; Figure) . This gave us a sample of 932, including 142 dementia cases and 790 controls, as determined by the subject's status at his last visit before 2000. When we assayed the samples, 242 (including all examination 3 and 5 L3 samples) were poor quality and were excluded from the analysis. The 682 with successfully processed plasma A␤ included 590 controls and 92 cases of dementia. Comparing the included to excluded controls, there were no significant differences in age at examination 3, midlife and late-life BPs, or stroke and diabetes mellitus history. Similarly, these variables did not differ between the included and excluded cases, nor did the distribution of dementia subtype cases differ.
For the final analysis we focused on AD and VaD cases; VaD cases were included based on reports of an association between plasma A␤ levels and vascular dementia. 17 We excluded the 15 subjects diagnosed with dementias other than AD or VaD. A further 8 subjects with missing data on any 1 of the covariates were excluded, giving an analytic sample of 667. This sample included 77 cases of dementia that were subtyped as follows: (1) 53 "all AD" (includes participants diagnosed with AD with or without contributing cardiovascular disease); (2) 38 cases of "pure AD" (the subset of all AD that were diagnosed with AD and no contributing cardiovascular disease); and (3) 24 cases of VaD (with no contribution of AD pathology). Of the 667, 73 subjects (including 24 cases) also participated in the autopsy substudy. Compared with the other participants seen at the HHP/HAAS examination 4, this subsample was younger and had significantly higher levels of total cholesterol and triglycerides and lower levels of high-density lipoprotein (Table  S1 , available in the online-only Data Supplement), as would be expected based on the design of the lipoprotein substudy.
Statistical Analysis
Subject characteristics were compared across BP strata, A␤1-40 and A␤1-42 quartiles, and presence of dementia, with linear and logistic regression adjusting for age at examination 3. For analyses of A␤1-40 and A␤1-42 as continuous measures, the distributions were normalized by log-transforming the values. The A␤40/42 ratio was calculated as [log(A␤1-40)]/[log(A␤1-42)]. Linear regression was used to examine the association of midlife BP to plasma A␤.
Cox proportional hazards regression was used to analyze the associations of late-life dementia to midlife BP and A␤ with age at examination 3 as the measure of follow-up time. 32 Subjects were left censored at the age of study entry and right censored at the age of event defined as follows: for prevalent dementia cases at examination 4, the event was dated 2 years before examination 4, and for incident dementia cases at exams 5 to 7, the event was dated halfway between the incident examination and the examination immediately preceding. Participants were censored at the date of death for patients who died with no dementia diagnosis and at the end of follow-up for participants not diagnosed with dementia. BP and log-transformed A␤ were standardized to evaluate the risk of dementia for every 1-SD change. In the BP and A␤ analyses, respectively, nonlinear associations were examined by entering quadratic and single terms into the model; the quadratic terms were not significant. To control for confounding and to reduce variation from known factors, our final models were adjusted for education (number of years of formal education), apolipoprotein E genotype (any 2, any 4, 3/3, and a dummy variable for missing genotype data; nϭ34), and time between the event and the date of blood draw for the A␤ measures. We included in the models the other putative confounders described above, but the conclusions were not changed. These variables were subsequently removed from the models, because the sample size in the higher BP range was relatively small, and the models became unstable as more variables were included.
For the AD models, we tested the interaction between A␤ and BP by including in the models the cross-product term "A␤ϫBP," with main effect terms of each. There was evidence of interaction between BP and A␤ with AD (statistical significance of interaction terms at PϽ0.10). To better understand and visualize these interactions, we examined the association of A␤ and BP to AD within BP strata defined as follows: systolic BP, Ͻ110 mm Hg, 110 to 139 mm Hg, and Ն140 mm Hg; diastolic BP, Ͻ80 mm Hg, 80 to 89 mm Hg, and Ն90 mm Hg. All of the analyses were adjusted for education, apolipoprotein E genotype, and the number of days between the A␤ blood draw and the censor date.
To a large extent, plasma A␤ reflects the balance between the build-up of A␤ in the brain and its clearance through cerebral vessels. 33 Therefore, there should be evidence in neuropathologic data that is concordant with the findings based on the plasma A␤ data. To this end we examined the association of A␤ tertiles to neuropathology. For plaque and tangle pathology, we used regression models based on a Poisson distribution, and for CAA we used models based on a binomial distribution. Because of the relatively small sample size, models were only adjusted for age and interval between blood draw and death. Analyses were conducted with SAS statistical software, release 9.1 (SAS Institute, Cary, NC).
No. Plasma samples
Results
Participants were a mean age of 58.9 years (range: 52.0 -73.0 years) at examination 3, mean age of 67.2 years (range: 61.0 -82.0 years) when the plasma sample for A␤ was obtained, and a mean age of 83.0 years (range: 72.0 -97.0 years) at the diagnosis/censoring event. The average time between the plasma draw and event was 15.8 years. Plasma A␤1-40 levels were higher as examination 3 age, BP, and lipid levels increased (Table 1) . Plasma A-42 levels increased as examination 3 BP and high-density lipoprotein levels increased. Additional subject characteristics by quartile of plasma A␤1-40 and A␤1-42 levels and by dementia type are given in Tables S2 to S4 .
Plasma A␤, Dementia 15 Years Later, and Neuropathology
One-SD decrease in plasma A␤1-40 and in plasma A␤1-42 was significantly associated with an increased risk for all AD and for pure AD ( Table 2 ). The linear trend for risk of AD across A␤ quartiles was also significant (A␤1-40 P linear trend Ͻ0.001; A␤1-42 P linear trend ϭ0.01). A lower A␤1-40/A␤1-42 ratio was significantly associated with a decreased risk of AD (P linear trend Յ0.05). Plasma A␤ levels were not associated with VaD in the main effects analyses. The prevalence of CAA increased significantly as the tertile of plasma A␤1-42 levels decreased and as the tertiles of A␤1-40/A␤1-42 ratio increased (Table 3) . No statistical trends were found in the average number of neocortical neuritic plaques or neurofibrillary tangles across tertiles of A␤1-40, A␤1-42, or the A␤1-40/A␤1-42 ratio (Table S5) .
Interaction Among BP, A␤, and the Risk for Dementia Subtype
A␤1-40 and A␤1-42 levels increased as diastolic and systolic BPs increased (Table 1 ). In the all-AD models, the interaction between A␤1-40 and diastolic BP (DBP; PϽ0.05) and between A␤1-42 and DBP (PϽ0.07) provided significant evidence of interaction. The interaction suggested that the risk for all AD increased with each SD decrease in plasma A␤, but the risk logarithmically increased as DBP increased. To better understand the interaction, we examined the association of A␤ levels within strata of DBP (Table 4 ). The risk estimates of A␤ levels to all AD were significantly higher in the high DBP group (for A␤1-40, Pϭ0.05; for A␤1-42, Pϭ0.03; for the ratio A␤1-40/A␤1-42, Pϭ0.08). Trends were similar in the pure AD analyses; the interaction between DBP and A␤1-40 was significant (Pϭ0.1). Models for AD and systolic BP or AD and pulse pressure did not suggest interaction.
Comment
Decreased plasma A␤1-40 and A␤1-42 levels were associated with an increased risk of AD ascertained, on average, 15 years after the plasma sample was obtained. The association was modulated by BP levels measured on average 25 years before AD was diagnosed. We also found evidence of synergism between DBP and A␤ levels such that the risk estimate for AD and decreasing A␤ levels increased as DBP increased. As plasma A␤1-42 levels decreased and the A␤1-40/A␤1-42 increased, the likelihood of CAA increased but not neuritic plaques or neurofibrillary tangles in brain tissue examined postmortem. This autopsy finding lends support to our finding of lower plasma levels of AB being indicative of higher risk for dementia and importantly also provides clues about a possible mechanism.
It is increasingly accepted that AD develops over a long period of time. 10 Our study provides insight into how the association of plasma A␤1 to clinical AD and pathological AD lesions may evolve over a time period that is longer than has been reported previously. [15] [16] [17] [18] [19] Strengths of this study *Data show mean (SD) unless otherwise indicated. †Data were log-transformed and standardized. ‡Data were adjusted for age at exam 3, ␤ for 1 SD increase. §PՅ0.05. Data were adjusted difference with reference. #Data show adjusted mean. **Triglycerides are log-transformed and standardized for computation of ␤.
include the following: (1) multiple, long-term follow-up visits for diagnoses of dementia in late life; (2) the availability of A␤ levels measured from plasma drawn 15 years before diagnosis; (3) the measure of midlife BP, before the age-and dementia-related drop in BP 6 ; and (4) the availability of autopsy material to gain insight into possible mechanisms.
There are several factors to take into account when interpreting the results. The number of cases is relatively limited, particularly in the upper strata of BP. Although there are few community-based studies to replicate these findings, these results can be further studied in animal models. Also, the sample is composed of Japanese-American men, so differential findings by sex or ethnic/race cannot be evaluated.
Many physiological issues related to these findings require further research. The cohort included subjects with elevated lipid levels. Lipid transport plays an important role in maintaining neuronal health. 34 However, without more understanding about the extent to which peripheral lipid levels reflect cerebral physiology, it is difficult to determine the extent to which having an enriched sample of subjects with high lipid levels affects the results; further investigation is warranted. Another issue in need of investigation is whether there is a physiological reason why diastolic BP is more significant in this analysis than systolic BP is. Possibly, the strength of the association depends on treatment protocols during the time that the BP is measured or aging of the arteries during the period when the trajectory BP is measured. This cohort was midlife in the late 1960s, when diastolic hypertension was the main reason for treatment. It is not yet clear whether there are other physiological reasons for differences in results between the 2 measures or how measures such as pulse pressure can be associated with late-life cognitive outcomes. Finally, circulating A␤ levels do not reflect non-A␤ amyloid species that might play a role in AD and may reflect infrequent disease states, such as amyloidosis. 35 In addition, plasma A␤ only provides an indirect measure of brain-specific A␤ pathology, and we only have one measure. In vivo analysis of brain-specific A␤ burden (eg, with positron emission tomography) could allow more accurate measures of A␤ burden and how it changes over time.
Within the limits of what circulating plasma A␤ levels may reflect, there is a strong positive correlation between plasma A␤ and A␤ in cerebrospinal fluid, 33 and studies have shown, for example, significant decreases in cerebrospinal fluid and plasma A␤ levels coincident with A␤ deposition in brain tissue of the Tg2576 transgenic mouse model of AD. 36 This inverse relationship is consistent with our findings of low plasma A␤ levels from 15 years before the clinical presentation of AD and our findings of more CAA as the level of plasma A␤ decreased.
Results from other studies of AD and A␤ vary from a higher baseline level of plasma A␤ being associated with an increased risk for AD 16, 17 to no association after multivariate adjustment. 18 It is important to emphasize that the follow-up *Hazard ratio (95% CI) was adjusted for apolipoprotein E genotype, education, and time from blood draw to censoring event.
†P linear trend Ͻ0.05. time in the present study was longer, and participants were younger at baseline, than in the related studies, and we had autopsy data to assess the consistency of our clinical findings. We also examined plasma A␤1-40 and A␤1-42 in the context of BP levels. Our finding of an interaction between A␤ and diastolic BP suggests that BP modulates the association of peripheral A␤ levels and AD. This modulation can reflect different pathways to A␤ deposition. One hypothesis to consider given our autopsy findings is that the vasoactive properties of A␤ in combination with high BP can greatly weaken vessel walls and reduce amyloid clearance from the brain, lead to capillary occlusion and hypoperfusion, or co-occur with an upregulation of angiotensin-converting enzyme and subsequent adverse changes, such as inflammation and apoptosis. [37] [38] [39] [40] The trajectory of amyloid changes to AD progression is still not well articulated, but our findings suggest that vascular integrity is an important component of the trajectory early on. Importantly, the measures of BP and plasma A␤ levels were made 10 to 20 years before the diagnosis of AD, suggesting that early intervention for elevated BP is important to reducing the component of AD attributable to high BP.
Perspectives
In summary, we found a joint association of elevated midlife diastolic BP, lower plasma A␤ levels, and the risk for late-life AD. The lower levels of A␤ levels may reflect the deposition of the peptides in the brain, as was suggested by the finding of increased CAA and low plasma A␤ levels. These findings bring together research reporting that midlife BP increases the risk for AD, that A␤ plays an important role in the pathophysiology of AD, and, separately, that A␤ is vasoactive. If problems in amyloid processing begin early in the disease, and midlife chronic exposure to hypertension damages cerebral microvessels and small vessels, thus impairing clearance of A␤ from the brain, this argues for an impact on AD prevention of early programs to prevent and treat elevated BP levels.
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